MedImmune Ethyol, Neutrexin sNDA Trials To Be Concluded In 2000
Executive Summary
MedImmune expects to complete four Phase III trials in 2000 to gain additional indications for Ethyol and Neutrexin, Executive VP-R&D James Young, PhD, said at a biotechnology press briefing Jan. 6 in Gaithersburg, Md.